Effective use of transdermal drug delivery in children

被引:67
作者
Delgado-Charro, M. Begona [1 ]
Guy, Richard H. [1 ]
机构
[1] Univ Bath, Sch Pharm & Pharmacol, Bath BA2 7AY, Avon, England
关键词
Transdermal drug delivery; Transdermal patches; Paediatric dosage forms; Premature neonates; Iontophoresis; Skin; Stratum corneum; EPIDERMAL WATER-LOSS; DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; LIDOCAINE-PRILOCAINE PATCH; NEEDLE-FREE DEVICE; PERCUTANEOUS-ABSORPTION; NEWBORN-INFANTS; CHLORHEXIDINE GLUCONATE; BARRIER PROPERTIES; SKIN PHYSIOLOGY;
D O I
10.1016/j.addr.2013.11.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Transdermal administration offers a non-invasive and convenient method for paediatric drug delivery. The competent skin barrier function in term infants and older children limits both water loss and the percutaneous entry of chemicals including drugs; but the smaller doses required by children eases the attainment of therapeutic concentrations. Transdermal patches used in paediatrics include fentanyl, buprenorphine, clonidine, scopolamine, methylphenidate, oestrogens, nicotine and tulobuterol. Some patches have paediatric labelling supported by clinical trials whereas others are used unlicensed. Innovative drug delivery methods, such as microneedles and sonophoresis are being tested for their safety and efficacy; needleless injectors are primarily used to administer growth hormone; and two iontophoretic devices were approved for paediatrics. In contrast, the immature and rapidly evolving skin barrier function in premature neonates represents a significant formulation challenge. Unfortunately, this population group suffers from an absence of approved transdermal formulations, a shortcoming exacerbated by the significant risk of excessive drug exposure via the incompletely formed skin barrier. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:63 / 82
页数:20
相关论文
共 205 条
  • [1] TRANSEPIDERMAL WATER-LOSS AND ABSORPTION OF HYDROCORTISONE IN WIDESPREAD DERMATITIS
    AALTOKORTE, K
    TURPEINEN, M
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1993, 128 (06) : 633 - 635
  • [2] ABE T, 1978, CHEM PHARM BULL, V26, P1659
  • [3] Physiological skin conditions of preterm and term neonates
    Afsar, F. S.
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2010, 35 (04) : 346 - 350
  • [4] PERCUTANEOUS-ABSORPTION OF CHLORHEXIDINE IN NEONATAL CORD CARE
    AGGETT, PJ
    COOPER, LV
    ELLIS, SH
    MCAINSH, J
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 1981, 56 (11) : 878 - 891
  • [5] Development and in vitro evaluation of furosemide transdermal formulations using experimental design techniques
    Agyralides, GG
    Dallas, PP
    Rekkas, DM
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 281 (1-2) : 35 - 43
  • [6] Aitken J., 2013, ARCH DIS CHILD-FETAL
  • [7] Microneedle-mediated vaccine delivery: Harnessing cutaneous immunobiology to improve efficacy
    Al-Zahrani, Sharifa
    Zaric, Marija
    McCrudden, Cian
    Scott, Chris
    Kissenpfennig, Adrien
    Donnelly, Ryan F.
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (05) : 541 - 550
  • [8] Allen A, 2001, ARCH DERMATOL, V137, P747
  • [9] DEVELOPMENTAL ASPECTS OF PERCUTANEOUS CAFFEINE ABSORPTION IN PREMATURE-INFANTS
    AMATO, M
    HUPPI, P
    ISENSCHMID, M
    SCHNEIDER, H
    [J]. AMERICAN JOURNAL OF PERINATOLOGY, 1992, 9 (5-6) : 431 - 434
  • [10] PERCUTANEOUS CAFFEINE APPLICATION IN THE TREATMENT OF NEONATAL APNEA
    AMATO, M
    ISENSCHMID, M
    HUPPI, P
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 1991, 150 (08) : 592 - 594